ACTMonitor® Lung

Precision Medicine Assists In Cancer Monitoring

Grasps the Changes of Cancer Genomic Mutations After Treatment

In the history of cancer treatment, precision medicine is now endorsed as a modern and preferred way for a healthcare system to take care of its cancer patients. Challenges in identifying the right drug for every cancer patient, as new drugs are emerging for specific genomic mutations, can be tackled strategically by obtaining a cancer patient's unique cancer genomic profile. The acceleration of oncology drug approvals and the modernization of clinical trials with biomarker-based patients have progressed well, as these have been commitments of the US FDA from 2018. The wave of precision medicine has also increased the approvals of companion diagnostics, which has resulted in ACT Genomics' genomic profiling service being on the waiting list for US FDA approval.

Why You Need to Know About Precision Medicine

The top global pharma companies are increasingly conducting clinical trials using precision medicine, which requires a cancer patient's genomic information through genomic profiling. This evolution has been felt by most hospitals, so it is increasingly more likely that genomic profiling will be required if you wish to try a new treatment option.

What Can a Blood Test Do for Me?

Even the best plans need constant monitoring and adjustment to keep up with changes. The complexity of a cancer cell makes it like a multifaceted beast, where when one side is being controlled, another side rages. While cells sporadically release DNA into blood, if the DNA released from a tumor, circulating tumor DNA (ctDNA), can be captured and analyzed by cancer genomic profiling, more real-time clues from the cancer cell can be revealed. Through a simple blood test, drug resistance is no longer a hindrance, and this test can also detect any signals of relapse and serve as a non-invasive alternative option to surgical biopsies.

Common Problems Associated with Cancer Treatment

∙ Chemotherapy and surgery are the only options recommended by the NCCN guidelines or single-gene testing results.
∙ Complications and metastases make it difficult to determine an appropriate drug.
∙ Ineffective treatment and cancer relapse after targeted therapy.

Diagnostic Solutions for Various Cancers

Through next-generation sequencing (NGS), ACTMonitor® Lung cancer monitoring testing decodes 11 genes to map drug options based on thorough clinical research, is not limited to a single clinical treatment guideline and determines the growth mechanism on a genomic level to provide more treatment strategy options with a higher success rate.

As single gene testing only provides very limited results, NGS genomic profiling can detect any special genomic mutations to result in a more effective treatment; if recurrence or metastases are found, treatment can be modified according to the NGS genomic profiling result to overcome drug resistance.

Treatment Advantages from Monitoring

✔ More humanized process: Avoids multiple biopsies and the time cost associated with single-gene testing, as only a small specimen is required for the simultaneous detection of various genes.

✔ More ideal treatment: Nominates proper targeted options.

✔ More intelligent budgeting: Evaluates options before treatment, according to genomic information, to ensure success rate and avoid wasting of funds.

Type of patients
∙ Who are unable to undergo surgery
∙ Who have developed drug resistance
∙ With risk of cancer recurrence
∙ Who wish to monitor treatment response

Specimen requirements
Blood

Turnaround time
10 working days^*